Tracers / [68Ga]NOTA-A1-His

[68Ga]NOTA-A1-His

Also written as [Ga-68]Ga-NOTA-A1-His
Radionuclide
Ga-68 t½ 67.71 min
Modality
Therapy
Production route
Stage
preclinical study
Syntheses indexed
1

What it is

Compound class
NOTA-conjugated anti-mesothelin single-domain antibody (nanobody)
Target / mechanism
Mesothelin PMID 40833585
Clinical application
PET imaging of mesothelin-expressing tumors (mesothelin-overexpressing cancers) PMID 40833585
Theranostic pair

Regulatory status

FDA
EMA (centralised)
Other approvals
Brand names

Clinical use

Typical injected activity
Uptake time

Reported in the literature. Not a dosing recommendation.

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
Manual synthesisSPE98 ± 1%p-SCN-Bn-NOTA-A1-His40833585
2025 EJNMMI Radiopharm Chem
100 µg of DOTA- or NOTA-conjugated A1-His (7 nmoles) in 1 M ammonium acetate were added to Ga-68 eluate (145–222 MBq).

Need this precursor?We can point you to suppliers for [68Ga]NOTA-A1-His, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 40833585. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 40833585: 'p-SCN-Bn-NOTA-A1-His'. Stage set/updated at stage 23 from PMID 40833585: 'Biodistribution and imaging studies in mice bearing mesothelin-expressing tumors showed specific tumor targeting for both tracers.'.